Download PDF
Klin Monbl Augenheilkd 2017; 234(04): 487-492
DOI: 10.1055/s-0042-121575
Klinische Studie
Georg Thieme Verlag KG Stuttgart · New York

Efficacy of Vitrectomy Combined with Subretinal rtPA Injection with Gas or Air Tamponade

Vitrektomie mit subretinaler rtPA-Injektion kombiniert mit Gas- oder Luftendotamponade
M. Waizel
1   University Eye Clinic Basel, Centre for Ophthalmology, Basel, Switzerland
2   Knappschaft Eye Clinic Sulzbach, Knappschaft Hospital Saar, Sulzbach/Saar
,
M. G. Todorova
1   University Eye Clinic Basel, Centre for Ophthalmology, Basel, Switzerland
,
A. Rickmann
2   Knappschaft Eye Clinic Sulzbach, Knappschaft Hospital Saar, Sulzbach/Saar
,
B. R. Blanke
3   University Eye Clinic Tuebingen, Centre for Ophthalmology, Tuebingen
,
P. Szurman
2   Knappschaft Eye Clinic Sulzbach, Knappschaft Hospital Saar, Sulzbach/Saar
3   University Eye Clinic Tuebingen, Centre for Ophthalmology, Tuebingen
› Author Affiliations
Further Information

Publication History

Publication Date:
31 January 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Background Functional and anatomical outcome after vitrectomy with rtPA combined with gas or air tamponade.

Patients and methods Retrospective analysis of pseudophakic patients treated with subretinal rtPA and gas or air tamponade. The primary endpoint was displacement of haemorrhage six months after surgery. The secondary endpoints were visual acuity (BCVA), haemorrhage diameter (MHD) and central macular thickness (CMT), as measured by SD-OCT.

Results 53 of 85 eyes were pseudophakic. 27 of these eyes were treated with air tamponade and 26 with gas tamponade. For patients with air tamponade, the mean BCVA improved from 20/530 to 20/355 (p = 0.01). MHD and CMT decreased from 6386 ± 2281 µm to 3805 ± 2397 µm (p < 0.001) and 895 ± 592 µm to 532 ± 386 µm (p < 0.001), respectively. For patients with gas tamponade, the mean BCVA improved only slightly, from 20/471 to 20/394 (p = 0.17). MHD and CMT exhibited statistically significant decreases from 6759 ± 1773 µm to 3525 ± 1548 µm (p < 0.001) and 1089 ± 587 µm to 537 ± 251 µm (p < 0.001), respectively.

Conclusions Vitrectomy with subretinal rtPA injection has strong functional and anatomical effects on submacular haemorrhages with both gas and air tamponade.

Zusammenfassung

Hintergrund Ziel der Studie war es die funktionellen und anatomischen Ergebnisse nach einer Vitrektomie mit subretinaler Recombinant-tissue-plasminogen-(rtPA-)Injektion kombiniert mit Gas- gegen Luftendotamponade zu vergleichen.

Patienten und Methoden Retrospektive Analyse von Patienten mit subretinaler Massenblutung, die mit Vitrektomie, subretinaler rtPA-Injektion und Gas- oder Luftendotamponade behandelt wurden. Primärer Endpunkt war die Verdrängung der Blutung 6 Monate nach der Behandlung. Sekundäre Endpunkte waren der bestkorrigierte Visus (BCVA), maximaler Durchmesser der Blutung (MHD) und die zentrale Makulaschichtdicke (CMT), jeweils gemessen mit optischer Kohärenztomografie.

Ergebnisse Von 85 Augen waren 53 pseudophak. Davon wurden 27 mit Luft- und 26 mit Gasendotamponade behandelt. Mit Luft behandelte Augen verbesserten sich signifikant von 20/530 auf 20/355 Snellen Visus (p = 0.01). MHD und CMT sanken signifikant von 6386 ± 2281 µm auf 3805 ± 2397 µm (p < 0.001) bzw. von 895 ± 592 µm auf 532 ± 386 µm (p < 0.001). Der Visus der mit Gas behandelten Augen verbesserte sich hingegen nur geringfügig von 20/471 auf 20/394 (p = 0.17). MHD und CMT sanken aber statistisch signifikant von 6759 ± 1773 µm auf 3525 ± 1548 µm (p < 0.001) bzw. von 1089 ± 587 µm auf 537 ± 251 µm (p < 0.001).

Schlussfolgerungen Vitrektomie mit subretinaler rtPA-Injektion hat einen starken funktionellen und anatomischen Effekt auf submakuläre Blutungen sowohl mit Gas- als auch Luftendotamponade.

Key words

subretinal haemorrhage - subretinal rtPA - subretinal recombinant tissue plasminogen activator - gas tamponade - air tamponade

Schlüsselwörter

subretinale Blutung - subretinale rtPA-Behandlung - Gastamponade - Lufttamponade
 

  • References

  • 1 Kiernan DF, Hariprasad SM, Rusu IM. et al. Epidemiology of the association between anticoagulants and intraocular hemorrhage in patients with neovascular age-related macular degeneration. Retina 2010; 30: 1573-1578
    CrossrefPubMedGoogle Scholar
  • 2 Toth CA, Morse LS, Hjelmeland LM. et al. Fibrin directs early retinal damage after experimental subretinal hemorrhage. Arch Ophthalmol 1991; 109: 723-729
    CrossrefPubMedGoogle Scholar
  • 3 Benner JD, Hay A, Landers 3rd MB. et al. Fibrinolytic-assisted removal of experimental subretinal hemorrhage within seven days reduces outer retinal degeneration. Ophthalmology 1994; 101: 672-681
    CrossrefPubMedGoogle Scholar
  • 4 Van Zeeburg EJ, van Meurs JC. Literature review of recombinant tissue plasminogen activator used for recent-onset submacular hemorrhage displacement in age-related macular degeneration. Ophthalmologica 2013; 229: 1-14
    CrossrefPubMedGoogle Scholar
  • 5 De Juan jr. E, Machemer R. Vitreous surgery for hemorrhagic and fibrous complications of age-related macular degeneration. Am J Ophthalmol 1988; 105: 25-29
    CrossrefPubMedGoogle Scholar
  • 6 Vander JF, Federman JL, Greven C. et al. Surgical removal of massive subretinal hemorrhage associated with age-related macular degeneration. Ophthalmology 1991; 98: 23-27
    CrossrefPubMedGoogle Scholar
  • 7 Peyman GA, Nelson jr. NC, Alturki W. et al. Tissue plasminogen activating factor assisted removal of subretinal hemorrhage. Ophthalmic Surg 1991; 22: 575-582
    PubMedGoogle Scholar
  • 8 Lewis H. Intraoperative fibrinolysis of submacular hemorrhage with tissue plasminogen activator and surgical drainage. Am J Ophthalmol 1994; 118: 559-568
    CrossrefPubMedGoogle Scholar
  • 9 Bressler NM, Bressler SB, Childs AL. et al. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report no. 13. Ophthalmology 2004; 111: 1993-2006
    CrossrefPubMedGoogle Scholar
  • 10 Treumer F, Roider J, Hillenkamp J. Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage. Br J Ophthalmol 2012; 96: 708-713
    CrossrefPubMedGoogle Scholar
  • 11 Hillenkamp J, Surguch V, Framme C. et al. Management of submacular hemorrhage with intravitreal versus subretinal injection of recombinant tissue plasminogen activator. Graefes Arch Clin Exp Ophthalmol 2010; 248: 5-11
    CrossrefPubMedGoogle Scholar
  • 12 Olivier S, Chow DR, Packo KH. et al. Subretinal recombinant tissue plasminogen activator injection and pneumatic displacement of thick submacular hemorrhage in age-related macular degeneration. Ophthalmology 2004; 111: 1201-1208
    CrossrefPubMedGoogle Scholar
  • 13 Waizel M, Todorova MG, Kazerounian S. et al. Efficacy of vitrectomy combined with subretinal recombinant tissue plasminogen activator for subretinal versus subpigment epithelial versus combined hemorrhages. Ophthalmologica 2016; 236: 123-132
    CrossrefPubMedGoogle Scholar
  • 14 Guthoff R, Guthoff T, Meigen T. et al. Intravitreous injection of bevacizumab, tissue plasminogen activator, and gas in the treatment of submacular hemorrhage in age-related macular degeneration. Retina 2011; 31: 36-40
    CrossrefPubMedGoogle Scholar
  • 15 Mayer WJ, Hakim I, Haritoglou C. et al. Efficacy and safety of recombinant tissue plasminogen activator and gas versus bevacizumab and gas for subretinal haemorrhage. Acta Ophthalmol 2013; 91: 274-278
    CrossrefPubMedGoogle Scholar
  • 16 De Jong JH, van Zeeburg EJ, Cereda MG. et al. Intravitreal versus subretinal administration of recombinant tissue plasminogen activator combined with gas for acute submacular hemorrhages due to age-related macular degeneration: an exploratory prospective study. Retina 2016; 36: 914-925
    CrossrefPubMedGoogle Scholar
  • 17 Singh RP, Patel C, Sears JE. Management of subretinal macular haemorrhage by direct administration of tissue plasminogen activator. Br J Ophthalmol 2006; 90: 429-431
    CrossrefPubMedGoogle Scholar
  • 18 Thompson JT, Sjaarda RN. Vitrectomy for the treatment of submacular hemorrhages from macular degeneration: a comparison of submacular hemorrhage/membrane removal and submacular tissue plasminogen activator-assisted pneumatic displacement. Trans Am Ophthalmol Soc 2005; 103: 98-107
    PubMedGoogle Scholar
  • 19 Sandhu SS, Manvikar S, Steel DH. Displacement of submacular hemorrhage associated with age-related macular degeneration using vitrectomy and submacular tPA injection followed by intravitreal ranibizumab. Clin Ophthalmol 2010; 4: 637-642
    PubMedGoogle Scholar
  • 20 Chang W, Garg SJ, Maturi R. et al. Management of thick submacular hemorrhage with subretinal tissue plasminogen activator and pneumatic displacement for age-related macular degeneration. Am J Ophthalmol 2014; 157: 1250-1257
    CrossrefPubMedGoogle Scholar
  • 21 Haupert CL, McCuen 2nd BW, Jaffe GJ. et al. Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid-gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration. Am J Ophthalmol 2011; 131: 208-215
    PubMedGoogle Scholar